Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07278557 · ClinicalTrials.gov registry record · Phase 2
Sparing Parotid Ducts Via MRI Sialography for Reduced Patient-Reported Xerostomia
A Phase 2 study of Head and Neck Cancer, sponsored by UNC Lineberger Comprehensive Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 98
- Enrollment target
- 1
- Study location
NCT07278557 is a Phase 2 study of Head and Neck Cancer that is actively recruiting participants, run by UNC Lineberger Comprehensive Cancer Center. The registered enrollment target is 98 participants, below the 260-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (62% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07278557, a Phase 2 study of Head and Neck Cancer, is actively recruiting participants, sponsored by UNC Lineberger Comprehensive Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 98 participants
- Enrollment target
- 1
- Study location
Study Summary
Radiation-induced xerostomia (dry mouth) is one of the most common and severe side effects for patients receiving radiation therapy for head and neck cancer. New approaches are needed to reduce this side effect and improve patients' quality of life after treatment. This is a Phase II, single-center, double-masked, parallel-arm, randomized controlled trial. It compares MRI-guided parotid ductal sparing to the standard approach of mean parotid gland sparing, focusing on patient-reported dry mouth outcomes in individuals receiving definitive radiotherapy for oropharyngeal cancer.
Conditions Studied
Interventions
- DEVICE MRI sialography
- OTHER Parotid Duct Sparing Radiation Therapy Planning
- OTHER Parotid Sparing Radiation Therapy Planning
Study Locations (1)
North Carolina
- University of North Carolina at Chapel Hill, Department of Radiation Oncology - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2026-01-28 |
| Est. Completion | 2030-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07278557
The ClinicalTrials.gov registry entry for NCT07278557 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 98 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 260-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (62% lower). The listed sponsor is UNC Lineberger Comprehensive Cancer Center, which has 366 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Head and Neck Cancer appearing as the primary indexed condition, and to 3 interventions - of which MRI sialography is the first listed.
NCT07278557 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT07278557 about?
NCT07278557 is a clinical study titled "Sparing Parotid Ducts Via MRI Sialography for Reduced Patient-Reported Xerostomia". Radiation-induced xerostomia (dry mouth) is one of the most common and severe side effects for patients receiving radiation therapy for head and neck cancer. New approaches are needed to reduce this side effect and improve patients' quality of life after treatment. This is a Phase II, single-center...
What is the current status of trial NCT07278557?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 98 participants. The study started on 2026-01-28. Estimated completion is 2030-02.
What conditions does trial NCT07278557 study?
This clinical trial studies the following conditions: Head and Neck Cancer.
What interventions are being tested in trial NCT07278557?
The interventions under investigation include: MRI sialography (DEVICE), Parotid Duct Sparing Radiation Therapy Planning (OTHER), Parotid Sparing Radiation Therapy Planning (OTHER).
Who is sponsoring clinical trial NCT07278557?
This trial is sponsored by UNC Lineberger Comprehensive Cancer Center, which has 366 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07278557 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Head and Neck Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase II Panitumumab-IRDye800 in Head & Neck Cancer
RECRUITING · Phase 2
-
ATATcH Alternating Treatment Plans for Advanced Cancer
RECRUITING · Phase 2
-
A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer
RECRUITING · Phase 2
-
Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)
RECRUITING · Phase 2
-
PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC
RECRUITING · Phase 2
-
A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Unknown Primary Head and Neck Cancer (ILLUMINATE STUDY)
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.